Search

Your search keyword '"Djenolan, Van Mourik"' showing total 3 results
Start Over Author "Djenolan, Van Mourik" Topic humans
3 results on '"Djenolan, Van Mourik"'

1. The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant

Author

Priya Vart, Wouter B Mattheussens, Marion Koopmans, Gerco den Hartog, Dimitri A. Diavatopoulos, Luuk B. Hilbrands, Marlies E J Reinders, Djenolan van Mourik, Renate G. van der Molen, Celine Imhof, Marieke van der Heiden, Daryl Geers, C. Baan, Frederike J. Bemelman, Rory D. de Vries, Marcia M L Kho, S Reshwan K Malahe, Debbie van Baarle, Rob van Binnendijk, Ester B. M. Remmerswaal, Jan-Stephan F. Sanders, Corine H. GeurtsvanKessel, Ron T. Gansevoort, Nynke Y. Rots, A. Lianne Messchendorp, Sophie C Frölke, Internal Medicine, Virology, Nephrology, AII - Inflammatory diseases, APH - Aging & Later Life, Infectious diseases, Graduate School, Experimental Immunology, Groningen Institute for Organ Transplantation (GIOT), Groningen Kidney Center (GKC), Translational Immunology Groningen (TRIGR), and Cardiovascular Centre (CVC)

Subjects
medicine.medical_specialty, COVID-19 Vaccines, medicine.medical_treatment, lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Renal Dialysis, Internal medicine, Medicine, Humans, Prospective Studies, Seroconversion, Renal Insufficiency, Chronic, Dialysis, Transplantation, Kidney, business.industry, Immunogenicity, Vaccination, Immunity, COVID-19, medicine.disease, Kidney Transplantation, medicine.anatomical_structure, Tolerability, Cohort, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], Kidney disease, 2019-nCoV Vaccine mRNA-1273
Abstract

BACKGROUND: In kidney patients COVID-19 is associated with severely increased morbidity and mortality. A comprehensive comparison of the immunogenicity, tolerability, and safety of COVID-19 vaccination in different cohorts of kidney patients and a control cohort is lacking.METHODS: This investigator driven, prospective, controlled multicenter study included 162 participants with chronic kidney disease (CKD) stages G4/5 (eGFR < 30 mL/min/1.73m2), 159 participants on dialysis, 288 kidney transplant recipients, and 191 controls. Participants received 2 doses of the mRNA-1273 COVID-19 vaccine (Moderna). The primary endpoint was seroconversion.RESULTS: Transplant recipients had a significantly lower seroconversion rate when compared with controls (56.9% versus 100%, P < 0.001), with especially mycophenolic acid, but also, higher age, lower lymphocyte concentration, lower eGFR, and shorter time after transplantation being associated with nonresponder state. Transplant recipients also showed significantly lower titers of neutralizing antibodies and T-cell responses when compared with controls. Although a high seroconversion rate was observed for participants with CKD G4/5 (100%) and on dialysis (99.4%), mean antibody concentrations in the CKD G4/5 cohort and dialysis cohort were lower than in controls (2405 [interquartile interval 1287-4524] and 1650 [698-3024] versus 3186 [1896-4911] BAU/mL, P = 0.06 and P < 0.001, respectively). Dialysis patients and especially kidney transplant recipients experienced less systemic vaccination related adverse events. No specific safety issues were noted.CONCLUSIONS: The immune response following vaccination in patients with CKD G4/5 and on dialysis is almost comparable to controls. In contrast, kidney transplant recipients have a poor response. In this latter, patient group development of alternative vaccination strategies are warranted.Supplemental visual abstract; http://links.lww.com/TP/C307.

Published
2022

2. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees

Author

Bas B. Oude Munnink, Rogier W. Sanders, Marc C. Shamier, Anouskha D. Comvalius, Djenolan van Mourik, Lennert Gommers, Corine H. GeurtsvanKessel, Jolieke A T van Osch, Gerco den Hartog, Nella N Nieuwkoop, Robert S. van Binnendijk, Marit J. van Gils, Laurine C Rijsbergen, Katharina S. Schmitz, Rik L. de Swart, Daryl Geers, Marion Koopmans, Tom G. Caniels, Emma Dijkhuizen, Rory D. de Vries, Richard Molenkamp, Bart L. Haagmans, Gaby Smits, Susanne Bogers, Herbert de Jager, Virology, Erasmus MC other, Graduate School, Medical Microbiology and Infection Prevention, and AII - Infectious diseases

Subjects
CD4-Positive T-Lymphocytes, 0301 basic medicine, COVID-19 Vaccines, T cell, Immunology, CD8-Positive T-Lymphocytes, Cross Reactions, Biology, Antibodies, Viral, Virus, Cell Line, 03 medical and health sciences, 0302 clinical medicine, Immune system, Antigen, SDG 3 - Good Health and Well-being, Immunity, medicine, Humans, 030212 general & internal medicine, SARS-CoV-2, Vaccination, COVID-19, General Medicine, 030104 developmental biology, medicine.anatomical_structure, Spike Glycoprotein, Coronavirus, Humoral immunity, biology.protein, Antibody, Immunologic Memory
Abstract

The emergence of SARS-CoV-2 variants harboring mutations in the spike (S) protein has raised concern about potential immune escape. Here, we studied humoral and cellular immune responses to wild type SARS-CoV-2 and the B.1.1.7 and B.1.351 variants of concern in a cohort of 121 BNT162b2 mRNA-vaccinated health care workers (HCW). Twenty-three HCW recovered from mild COVID-19 disease and exhibited a recall response with high levels of SARS-CoV-2-specific functional antibodies and virus-specific T cells after a single vaccination. Specific immune responses were also detected in seronegative HCW after one vaccination, but a second dose was required to reach high levels of functional antibodies and cellular immune responses in all individuals. Vaccination-induced antibodies cross-neutralized the variants B.1.1.7 and B.1.351, but the neutralizing capacity and Fc-mediated functionality against B.1.351 was consistently 2-to 4-fold lower than to the homologous virus. In addition, peripheral blood mononuclear cells were stimulated with peptide pools spanning the mutated S regions of B.1.1.7 and B.1.351 to detect cross-reactivity of SARS-CoV-2-specific T cells with variants. Importantly, we observed no differences in CD4+ T-cell activation in response to variant antigens, indicating that the B.1.1.7 and B.1.351 S proteins do not escape T-cell-mediated immunity elicited by the wild type S protein. In conclusion, this study shows that some variants can partially escape humoral immunity induced by SARS-CoV-2 infection or BNT162b2 vaccination, but S-specific CD4+ T-cell activation is not affected by the mutations in the B.1.1.7 and B.1.351 variants.

Published
2021

3. Temporal Dynamics of VEGFA-Induced VEGFR2/FAK Co-Localization Depend on SHB

Author

Ilkka, Pietilä, Djenolan, Van Mourik, Andreas, Tamelander, Vitezslav, Kriz, Lena, Claesson-Welsh, Anders, Tengholm, and Michael, Welsh

Subjects
Male, Vascular Endothelial Growth Factor A, SHB, endocrine system, Neovascularization, Physiologic, TIRF, Article, Mice, angiogenesis, Cell Movement, Proto-Oncogene Proteins, Animals, Humans, Adaptor Proteins, Signal Transducing, Mice, Knockout, Mice, Inbred BALB C, FAK, Endothelial Cells, respiratory system, focal adhesions, Vascular Endothelial Growth Factor Receptor-2, HEK293 Cells, VEGFR2, Focal Adhesion Protein-Tyrosine Kinases, cardiovascular system, Female
Abstract

Focal adhesion kinase (FAK) is essential for vascular endothelial growth factor-A (VEGFA)/VEGF receptor-2 (VEGFR2)-stimulated angiogenesis and vascular permeability. We have previously noted that presence of the Src homology-2 domain adapter protein B (SHB) is of relevance for VEGFA-stimulated angiogenesis in a FAK-dependent manner. The current study was conducted in order address the temporal dynamics of co-localization between these components in HEK293 and primary lung endothelial cells (EC) by total internal reflection fluorescence microscopy (TIRF). An early (

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results